close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tandem Diabetes Care, Inc. - Common Stock (NQ:TNDM)

14.87 -0.09 (-0.60%)
Streaming Delayed Price Updated: 3:11 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tandem Diabetes Care, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
1 Growth Stock with All-Star Potential and 2 to Keep Off Your Radar
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s... 
Via StockStory
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TNDM),(NYSE:NVO),(NASDAQ:PODD),(NYSE:MDT) EQNX::TICKER_END 
Via FinancialNewsMedia
Earnings Scheduled For April 30, 2025
 
Via Benzinga
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
From FN Media Group LLC
Via GlobeNewswire
Tandem Diabetes Inks Deal With Abbott For New Diabetes Solutions: Retail Sentiment Stays Subdued
The agreement is to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with San Diego, California- based Tandem's innovative insulin... 
Via Stocktwits
Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor
From Tandem Diabetes Care, Inc.
Via Business Wire
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges
Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral. 
Via Benzinga
Reflecting On Healthcare Technology Stocks’ Q1 Earnings: Tandem Diabetes (NASDAQ:TNDM)
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including Tandem Diabetes (NASDAQ:TNDM) and its peers. 
Via StockStory
Where Tandem Diabetes Care Stands With Analysts
 
Via Benzinga
Fortune Brands, Whirlpool, Align Technology, Tandem Diabetes, and STAAR Surgical Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the major indices pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that... 
Via StockStory
Topics Bonds Stocks
1 Momentum Stock with Impressive Fundamentals and 2 to Turn Down
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to new product launches, positive news, or even a dedicated social media... 
Via StockStory
TNDM Q1 Earnings Call: Product Expansion and Channel Initiatives Drive Growth Against Margin Pressures
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) announced better-than-expected revenue in Q1 CY2025, with sales up 22.3% year on year to $234.4 million. The company expects the full... 
Via StockStory
3 of Wall Street’s Favorite Stocks in Dangerous Territory
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Tandem Diabetes Care Announces Upcoming Conference Presentations
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem Diabetes Care Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)
 
Via Benzinga
Tandem Diabetes’s (NASDAQ:TNDM) Q1: Beats On Revenue, Stock Soars
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 22.3% year on year to $234.4 million. The company expects the full... 
Via StockStory
Tandem Diabetes (NASDAQ:TNDM) Posts Better-Than-Expected Sales In Q1, Stock Soars
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 22.3% year on year to $234.4 million. The company expects... 
Via StockStory
Tandem Diabetes Care Announces First Quarter 2025 Financial Results
From Tandem Diabetes Care, Inc.
Via Business Wire
Insights into Tandem Diabetes Care's Upcoming Earnings
 
Via Benzinga
Tandem Diabetes (TNDM) Q1 Earnings Report Preview: What To Look For
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) will be reporting results tomorrow after the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
1 Volatile Stock Worth Your Attention and 2 to Keep Off Your Radar
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
Q4 Earnings Outperformers: Tandem Diabetes (NASDAQ:TNDM) And The Rest Of The Healthcare Technology Stocks
Let’s dig into the relative performance of Tandem Diabetes (NASDAQ:TNDM) and its peers as we unravel the now-completed Q4 healthcare technology earnings season. 
Via StockStory
2 Beaten-Down Stocks to Avoid in the Tariff-Fueled Correction
Via The Motley Fool
Topics Artificial Intelligence Government World Trade
Forecasting The Future: 9 Analyst Projections For Tandem Diabetes Care
 
Via Benzinga
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry
Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest strain. Large biopharma firms remain protected, while medtech companies... 
Via Benzinga
Topics Government World Trade
Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025
From Tandem Diabetes Care, Inc.
Via Business Wire
3 Reasons to Sell TNDM and 1 Stock to Buy Instead
Shareholders of Tandem Diabetes would probably like to forget the past six months even happened. The stock dropped 54.1% and now trades at $20.22. This was partly driven by its softer quarterly results... 
Via StockStory
Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 Diabetes
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States
From Tandem Diabetes Care, Inc.
Via Business Wire
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today